Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PBYI > SEC Filings for PBYI > Form 8-K on 24-Oct-2012All Recent SEC Filings

Show all filings for PUMA BIOTECHNOLOGY, INC. | Request a Trial to NEW EDGAR Online Pro



Entry into a Material Definitive Agreement, Notice of Delisting or Failu

Item 1.01 Entry into a Material Definitive Agreement.

Underwriting Agreement

On October 18, 2012, Puma Biotechnology, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Swann LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), providing for the offer and sale in a firm commitment underwritten public offering (the "Offering") of 7,500,000 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a price of $16.00 per share (the "Public Offering Price"), less the underwriting discount. On October 19, 2012, the representatives of the Underwriters exercised the overallotment option granted to the Underwriters in the Underwriting Agreement to purchase an additional 1,125,000 shares of Common Stock from the Company at the Public Offering Price, less the underwriting discount.

The transactions contemplated by the Underwriting Agreement were consummated on October 24, 2012. The net proceeds received by the Company from the sale of 8,625,000 shares of Common Stock were approximately $129.1 million after deducting the underwriting discount and estimated offering expenses payable by the Company.

The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, a copy of which is attached hereto as Exhibit 1.1 and incorporated herein by reference.

Copies of the press releases issued by the Company in connection with the Offering are attached hereto as Exhibits 99.1, 99.2 and 99.3 and incorporated by reference herein.

Indemnification Agreements

On October 18, 2012, the Company entered into indemnification agreements (the "Indemnification Agreements") with each of the Company's executive officers and directors. The Company's current executive officers are Alan H. Auerbach, President and Chief Executive Officer, Charles R. Eyler, Senior Vice President, Finance and Administration and Treasurer, Richard P. Bryce, Senior Vice President, Clinical Research and Development, and Richard Phillips, Ph.D., Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance. The Company's current directors are Alan H. Auerbach, Thomas R. Malley and Jay M. Moyes.

Under the Indemnification Agreements, the Company has agreed to, among other things, indemnify these individuals against certain liabilities that may arise in connection with their status or service as one of the Company's executive officers or directors or in their capacity at other specified entities at which they may serve at the Company's request and to advance their expenses incurred as a result of any proceeding for which they may be entitled to indemnification. The Indemnification Agreements are intended to provide indemnification rights to the fullest extent permitted by the General Corporation Law of the State of Delaware and are in addition to any other rights these individuals may have under the Company's organizational documents or applicable law.

The foregoing description of the Indemnification Agreements is qualified in its entirety by reference to the form of Indemnification Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated by reference herein.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On October 19, 2012, the Company's Common Stock became listed and began trading on the New York Stock Exchange under the symbol "PBYI." Prior to this time, shares of the Company's Common Stock were quoted for trading on the OTC Bulletin Board and OTCQB Market.

Item 8.01 Other Events.

In connection with the registration statement relating to the Offering, the Company provided additional information about the Company and updated its risk factors and business description. The updated risk factors and business description are attached hereto as Exhibits 99.4 and 99.5, respectively, and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

1.1     Underwriting Agreement, dated October 18, 2012, among Puma Biotechnology,
        Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink
        Swann LLC, as representatives of the underwriters named therein

10.1    Form of Indemnification Agreement (incorporated by reference to Exhibit
        10.17 of the Company's Amendment No. 1 to the Registration Statement on
        Form S-1 filed on October 15, 2012)

99.1    Press Release dated October 18, 2012

99.2    Press Release dated October 22, 2012

99.3    Press Release dated October 24, 2012

99.4    Risk Factors

99.5    Business Description

  Add PBYI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PBYI - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.